Psychedelics
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has successfully demonstrated Proof of Concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of depression and addiction. Multiple long-acting psychedelic treatments have been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration […]
LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback VANCOUVER, BC, April 21, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE“) a leader in advanced proprietary technology for psychedelic therapy, is pleased […]
Novamind Collaborates with Center for Change
TORONTO, ON / ACCESSWIRE / April 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind”), a leading mental health company specialized in psychedelic medicine, has shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP). Novamind collaborated on the study with Center for Change, […]
Silo Wellness Announces Five New Psychedelic Wellness Retreats in Jamaica
MONTEGO BAY, Jamaica, April 21, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness”) (CSE: SILO) (FRA:3K70), a leading wellness company in the psychedelics and functional mushroom marketplaces, today announced a series of psilocybin-assisted wellness retreats beginning in May. Based in Montego Bay, these retreats are one component of Silo Wellness’ existing psilocybin operations in […]
Red Light Holland Increases Points of Sale for iMicrodose Packs in the Netherlands by More Than 140%
Toronto, Ontario–(Newsfile Corp. – April 21, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to provide an update on the […]
PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors
OXFORD, Ohio and COCONUT CREEK, Fla., April 21, 2021 /CNW/ — PsyBio Therapeutics Corp. (TSXV: PSYB) (“PsyBio“), a biotechnology company pioneering the next generation of targeted psychoactive medications, is pleased to announce the appointment of Mr. Bob Oliver to the Company’s board of directors (the “Board“), effective immediately. The Company is developing a platform technology […]
April 21, 2021 07:15 AM Eastern Daylight Time TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has successfully demonstrated Proof of Concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of depression and addiction. “This Proof-of-Concept data provides strong support […]
Lobe Sciences Appoints Benjamin Kelmendi, MD from Yale University to Scientific Advisory Board
Vancouver, British Columbia–(Newsfile Corp. – April 20, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board. Philip Young, CEO and Director of Lobe stated, “We are extremely […]
Nova Mentis Organizes Autism Data Bank in North America
VANCOUVER, BC, April 20, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be organizing a North American autism spectrum disorder (ASD) data bank to support the Company’s development of […]
TORONTO, April 20, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (“PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, today announced it submitted an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of […]
Silo Wellness Appoints Phytomedicine Business Leader as Board Member
TORONTO, April 20, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (CSE: SILO) (FRA:3K70), a wellness company in the psychedelics and functional mushroom marketplaces is pleased to announce today the appointment of its newest board member, Wayne Isaacs, a seasoned Jamaican-Canadian businessman and leader in natural, plant-based medicines. The appointment comes following the recent passing of […]
Tryp Therapeutics Reports on Key Milestones for 2021
San Diego, California–(Newsfile Corp. – April 20, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp“), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, reported today on the Company’s significant progress since successfully completing its Initial Public Offering in December 2020. Tryp is advancing two drug development […]
Beckley Psytech partners with Fluence to create psychedelic therapy training programme
April 20, 2021 – Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has partnered with specialist education platform Fluence to produce professional training materials for administering psychedelic-assisted therapy. Fluence and Beckley Psytech will collaborate to develop a training manual that will enable qualified healthcare professionals to deliver […]
Toronto, Ontario–(Newsfile Corp. – April 20, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset“) is pleased to announce, that based on data derived from Mindset’s in vivo testing program (i.e. testing in animal subjects) carried out by InterVivo Solutions Inc., the Company has confirmed that the majority of its patent pending compounds across four families […]
Tryp Therapeutics Reports on Key Milestones for 2021
San Diego, California–(Newsfile Corp. – April 20, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, reported today on the Company’s significant progress since successfully completing its Initial Public Offering in December 2020. Tryp is advancing two […]
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the formation of its Clinical Advisory Board, with the additions of Maurizio Fava, MD, Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital; Lynn Marie Morski, MD, Esq., President of the Psychedelic Medicine Association; and Anthony Back, MD, Professor in […]
Tryp Therapeutics Completes Up-Listing onto OTCQB and DTC Eligibility
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has successfully completed it’s up-listing onto the OTCQB® Venture Market (the “OTCQB“) and DTC eligibility, allowing for US shareholders to trade and purchase the company’s securities. The Company’s common shares can be found on the OTCQB under […]
KI findet die Nadel im Heuhaufen
Jedes Jahr werden Tausende von Molekülen als Medikamentenkandidaten für eine Vielzahl von Krankheiten hergestellt, synthetisiert und getestet. MagicMed Industries bringt diesen pharmazeutischen Entwicklungsansatz auf dem Gebiet der Psychedelika zum Einsatz, um neue therapeutische Alternativen für Patienten mit Problemen der Gehirn- und psychischen Gesundheit zu schaffen. Die Entdeckung der richtigen Moleküle ist jedoch ein gewaltiges […]
PharmaTher Provides Update on Psychedelic Product Programs
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (“PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, is pleased to provide an update on its psychedelic product programs as it relates to the clinical and commercial development of ketamine and the research and development of proprietary microneedle patch delivery systems for psychedelics […]
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness”) (CSE: SILO) (FRA:3K70), a wellness company in the psychedelics and functional mushroom marketplaces announced today that through its wholly-owned subsidiary, it has signed a binding Letter of Intent (LOI) for a multi-year patent licensing agreement with Jungle Med Inc. (“Jungle Med”), a human […]
Every year, thousands of molecules are being created, synthesized and tested as drug candidates for a vast number of ailments. MagicMed Industries brings this pharmaceutical development approach to the field of psychedelics to create new therapeutic alternatives for patients with brain and mental health indications. However, discovering the right molecules is a massive undertaking. It […]
Optimi Health Adds to Corporate and Advisory Team
VANCOUVER, BC (GLOBE NEWSWIRE – April 14, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the appointments of Dr. Azim Jamal to its Advisory Board, and Leah Hodges to the role […]
Psychedelics Then & Now: From Ancient Times to the Psychedelic Renaissance
Psychedelics have become one of the most promising classes of drugs in a generation, as well as an exciting new industry for investors. Despite their resurgence among researchers and investors, psychedelics have been used for thousands of years before they were criminalized in the 1970s in the United States and around the world. Let’s take […]
Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board
Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect. Bringing nearly two decades of experience in the pharmaceuticals industry, Adam served as Chief Financial Officer (CFO) for five years at GW Pharmaceuticals, the UK-based drug […]
TORONTO-April 13, 2021-(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced plans to advance the pre-clinical work for its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004, two of the Company’s deuterated tryptamine development candidates. These studies are part of the […]
Psychedelic Wellness-Focused Company Delic Holdings Provides First Quarter 2021 Shareholder Update
VANCOUVER, BC, April 12, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to provide the following shareholder update on its operations for the first quarter of 2021. The first quarter of 2021 has been transformative and expansive as DELIC has entered into new sectors of this […]
Psychedelics Wellness Company Delic: Proven Management Team with a Star-Studded Board
The psychedelics sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s […]
ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption VANCOUVER, BC, April 8, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”) a leader in advanced proprietary technology for psychedelic therapy, […]
VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize discussions with the U.S. Food and Drug Administration (“FDA”) by filing an End-of-Phase 2 meeting request (EOP2) based […]
The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories. VANCOUVER, BC / ACCESSWIRE / April 8, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce, further to […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
CanIDeal is the first fully-legal, B2B digital marketplace for the entire cannabis industry. The company’s mission is to provide an easy-to-use and safe ecommerce solution for entrepreneurs in the market for THC, CBD and ancillary products.
FSD Pharma is a publicly traded company on the Canadian Securities Exchange under the symbol HUGE. The Company, through its wholly-owned subsidiary FV Pharma Inc., holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). HUGE, made history on its first day of trading on the Canadian Securities […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
